The digital revolution has changed many aspects of our lives, including how we work, live, and play, from online fraud detection to artificial intelligence-powered online purchasing suggestions. How we satisfy our health demands and get healthcare is one of the most significant developments brought about by digital technology. To accomplish healthcare objectives, digital health leverages the potential of digital technology, including sophisticated analytics.

As a result, the sector has the chance to benefit everyone, including patients, healthcare professionals, and providers. It enhanced patient health outcomes through individualized treatment plans, reduced healthcare costs for both patients and providers, boosted operational efficiency at healthcare institutions, including hospitals, and extended access to healthcare to previously underserved populations.

Digital technologies have demonstrated benefits in cardiovascular disease (CVD) patients' morbidity and death outcomes when put into practice. Globally, CVDs continue to be the primary cause of mortality and disability. An estimated 523 million individuals worldwide suffered from CVD in 2020, accounting for around 32% of all fatalities worldwide. Within and within nations, different population groups bear an uneven share of the burden of CVD and the obstacles to its prevention and management. For example, the burden of CVD varies between Black and Hispanic individuals in the United States.

Over 80% of people with CVD are thought to reside in low- and middle-income countries (LMICs), which account for more than three-quarters of CVD mortality worldwide as compared to high-income countries (HICs). At this point, Cleerly establishes a new benchmark for cardiovascular treatment.

A New Standard for Cardiovascular Care

A digital healthcare startup called Cleerly is revolutionizing how doctors treat heart disease. In order to help clinicians accurately identify and define atherosclerosis earlier and provide individualized, life-saving treatment plans for all patients throughout their care continuum, their clinically proven, AI-based digital care platform integrates with coronary computed tomography angiography (CCTA) imaging.

Instead of measuring indirect indicators like risk factors and illness symptoms, they evaluate atherosclerosis, or the accumulation of plaque in the heart's arteries. Their AI-powered digital care route improves overall clinical and financial results by providing more straightforward, quicker, and more accurate heart disease evaluation and reporting that is customized for each stakeholder.

In contrast to indirect signs like disease symptoms and risk factors, Cleerly evaluates atherosclerosis, or the buildup of plaque in the arteries supplying the heart. By offering more efficient, rapid, and accurate heart disease assessment and reporting that is tailored for each stakeholder, their AI-powered digital care route enhances overall clinical and economic outcomes. They have carried out some of the largest clinical investigations in the last ten years to identify the most important indicators that go beyond symptoms that increase an individual's risk of experiencing a heart attack.

The most important heart disease test you may ever have

Cleerly for Individuals - Early Detection of Heart Disease

Cardiology has essentially been "sickcare" for more than 50 years, concentrating on heart disease symptoms rather than the underlying condition, atherosclerosis. It's the kind of atherosclerotic plaque accumulation that matters most, according to data from more than a decade of clinical trials.

Cleerly for Providers - AI takes us beyond a score—and transforms preventive heart care

In standard CCTA tests, the Cleerly Labs solution examines stenosis and atherosclerosis (plaque) non-invasively using FDA-approved machine learning algorithms. Their artificial intelligence algorithms identify the lumen and vessel walls, find and measure stenoses, identify, measure, and categorize plaque, and build a three-dimensional (3D) model of the patient's coronary arteries.

Cleerly for Payors and Insurance Provider - Today's Clinical Care Challenge

Patients with traditional risk factors but little disease are frequently taking diagnostic tests and undergoing needless procedures, while those with the highest burden of coronary artery disease (CAD) are frequently unaware of their condition.

Cleerly Comprehensive Care Management Platform

Precise AI-driven coronary CTA analysis

Utilizing coronary computed tomography angiography (CCTA) studies, Cleerly measures atherosclerosis (plaque), stenosis, and the risk of ischemia non-invasively utilizing patented and FDA-approved machine learning algorithms.

A 3D model of the patient's coronary arteries is created by their machine-learning AI, which also detects the lumen and vessel walls, finds and measures stenoses, and counts and classifies plaque. The Cleerly ISCHEMIA method calculates the probability of vessel-level ischemia using measures derived from invasive FFR data.

Clinical Evidence for Personalized Heart Attack Prevention

Personalized Heart Care Using Plaque Analysis Based on Science. Cleerly is an AI-powered coronary computed tomography angiography (CCTA) analysis that shows physicians the locations of plaque and stenosis in coronary arteries through comprehensive reporting. Cleerly's method is scientifically supported and is based on more than 10 million photos taken over 15 years from more than 40,000 patients.

Meet the Founder & CEO

James K. Min, MD the Founder & CEO of Cleerly

“To support adoption of our new standard of care, Cleerly developed a workflow solution that makes AI-enabled CCTA analysis and report distribution more seamless for providers.”